KeyCorp initiated coverage on shares of Acrivon Therapeutics (NASDAQ:ACRV - Free Report) in a research report sent to investors on Friday, MarketBeat.com reports. The brokerage issued an overweight rating on the stock.
A number of other brokerages also recently issued reports on ACRV. BMO Capital Markets decreased their price target on Acrivon Therapeutics from $28.00 to $27.00 and set an "outperform" rating for the company in a report on Thursday, November 14th. HC Wainwright reiterated a "buy" rating and issued a $22.00 target price on shares of Acrivon Therapeutics in a research note on Thursday, November 14th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $23.67.
Get Our Latest Analysis on ACRV
Acrivon Therapeutics Trading Up 5.3 %
ACRV traded up $0.30 during midday trading on Friday, hitting $5.87. 19,271 shares of the company were exchanged, compared to its average volume of 35,213. The company's 50 day simple moving average is $6.31 and its 200 day simple moving average is $7.32. The firm has a market capitalization of $182.67 million, a price-to-earnings ratio of -2.17 and a beta of 0.77. Acrivon Therapeutics has a 1-year low of $3.19 and a 1-year high of $11.90.
Institutional Investors Weigh In On Acrivon Therapeutics
A number of institutional investors have recently added to or reduced their stakes in ACRV. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Acrivon Therapeutics during the fourth quarter worth about $40,000. Dimensional Fund Advisors LP acquired a new stake in Acrivon Therapeutics in the 2nd quarter worth about $58,000. Barclays PLC increased its stake in Acrivon Therapeutics by 51.2% during the 3rd quarter. Barclays PLC now owns 33,306 shares of the company's stock worth $233,000 after buying an additional 11,273 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Acrivon Therapeutics by 548.3% during the third quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company's stock valued at $238,000 after acquiring an additional 28,748 shares during the last quarter. Finally, Exome Asset Management LLC purchased a new position in shares of Acrivon Therapeutics in the third quarter valued at approximately $817,000. Institutional investors and hedge funds own 71.62% of the company's stock.
About Acrivon Therapeutics
(
Get Free Report)
Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Read More
Before you consider Acrivon Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acrivon Therapeutics wasn't on the list.
While Acrivon Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
